Crowd of KOLs and DOLs

DOLs: A New Frontier

Whether you call them Key Opinion Leaders (KOLs) or Key External Experts (KEEs), success in the pharmaceutical space has always started with one essential task: identifying the right experts to engage, influence, and collaborate with. These are the clinicians who publish groundbreaking research, present at major conferences, and serve on Read more

By Jason Shaneyfelt, ago
Scientist in googles

Industry Happenings – October 2026

Learn how major industry trends are influencing the future of biopharma, including patent expiration challenges, evolving regulatory pathways, and emerging therapeutic targets that are attracting significant investment and attention. Source: PharmaVoice A wave of patent expirations is expected to put more than $500 billion in global prescription drug sales at Read more

By Jason Shaneyfelt, ago
Magnifying glass inspecting men in suits

Industry Happenings -September 2026

FDA policy, shifting R&D priorities, and heightened oversight of overseas trials are shaping the future of drug development. Don’t miss the latest in BioPharma! Source: PharmaVoice The upcoming reauthorization of the Prescription Drug User Fee Act (PDUFA) could create an opening for Congress to streamline U.S. clinical trials as competition Read more

By Jason Shaneyfelt, ago